Can a targeted drug slow deadly brain cancer?
Disease control
Completed
This phase II trial tests whether the experimental drug BKM120 can slow or stop the growth of recurrent glioblastoma, an aggressive brain cancer, in patients whose tumors have an activated PI3K pathway. Some participants take the drug before surgery to see if it reaches the brain…
Phase 2 • Sponsor: L. Nicolas Gonzalez Castro, MD, PhD • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC